Home / Health / Medicaid Cuts Halt Weight-Loss Drug Access

Medicaid Cuts Halt Weight-Loss Drug Access

Summary

  • Medicaid coverage for weight-loss drugs was stopped by four states.
  • GLP-1 prescriptions dropped by 84% in states that ended coverage.
  • Stopping GLP-1s can lead to weight regain and increased health risks.
Medicaid Cuts Halt Weight-Loss Drug Access

Four states—California, New Hampshire, Pennsylvania, and South Carolina—ceased Medicaid coverage for GLP-1 weight-loss medications on January 1, 2026, citing high costs. A study published in JAMA revealed a dramatic 84 percent reduction in prescriptions in these states compared to those that maintained coverage. Researchers analyzed Medicaid prescription data from January 2022 through March 2026.

This withdrawal of coverage has significant implications, as patients who stop GLP-1 medications often regain a substantial portion of lost weight. Studies indicate that stopping these drugs can also lead to a worsening of cardiometabolic risk factors. The study estimated that between 175,500 and 526,600 fewer beneficiaries in these four states likely filled prescriptions for weight-loss GLP-1s.

Experts emphasize that while access has changed, the need for treatment has not diminished. Patients who depended on Medicaid may struggle to afford out-of-pocket costs, creating a disparity in care. Clinicians suggest alternatives for patients losing coverage, including covered weight-management drugs, diet counseling, and structured programs.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571